Etanercept biosimilar - Protheragen
Alternative Names: Enbrel biosimilar - Protheragen; Pro-S02Latest Information Update: 28 Jul 2023
At a glance
- Originator Protheragen
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA (Parenteral)
- 27 Jun 2019 Etanercept biosimilar - Protheragen is available for licensing as of 13 Jun 2019. https://www.protheragen.com/
- 01 Jun 2019 Preclinical trials in Rheumatoid arthritis in USA (Parenteral) before June 2019 (Protheragen pipeline, June 2019)